C-reactive protein and lactate dehydrogenase as prognostic indicators in COVID-2019 outpatients

- 3 4
- 5 Keiko Suzuki¹, Takaya Ichikawa², Satoshi Suzuki¹, Yoko Tanino³, Yasutaka Kakinoki²
- 6
- 7 ¹ Department of general internal medicine, Asahikawa City Hospital, Asahikawa, Japan
- 8 ² Department of hematology, Asahikawa City Hospital, Asahikawa, Japan
- 9 ³ Department of respiratory medicine, Asahikawa City Hospital, Asahikawa, Japan
- 10
- 11 Corresponding Author:
- 12 Keiko Suzuki¹
- 13 Kinseichou-1choume, Asahikawa, Hokkaido, 070-8610, Japan
- 14 Email address: kii_suzu@yahoo.co.jp
- 15

16 Abstract

- 17 **Background.** It is critical for clinicians seeing outpatients with coronavirus disease 2019
- 18 (COVID-19) to identify those who will require oxygen therapy after the hospital visit. Although
- 19 studies on biomarkers predicting mortality or ventilator requirement in hospitalized patients with
- 20 COVID-19 have been conducted, research on biomarkers predicting the need for oxygen
- 21 therapy in outpatients is sparse.
- 22 Methods. Patients with COVID-19 who visited Asahikawa City Hospital on an outpatient basis
- 23 were included in the study. In total, 287 new outpatients visited between April 2021 and
- 24 September 2021, and 142 underwent blood testing. All blood tests were performed before any
- 25 treatments for COVID-19 were started. Demographic information, laboratory data, and clinical
- treatment information were extracted from the electronic medical records. Risk factorsassociated with oxygen therapy were explored.
- 28 **Results.** In total, 40 of 142 patients who underwent blood testing required oxygen therapy
- 29 within 7 days after blood samples were taken, and all other patients recovered without oxygen
- 30 therapy. C-reactive protein (CRP) and lactate dehydrogenase (LDH) levels were significantly
- 31 higher in patients who required oxygen therapy, and their cutoffs were 36 mg/L (sensitivity,
- 32 0.802; specificity, 0.725) and 267 U/L (sensitivity, 0.713; specificity, 0.750), respectively.
- 33 Multivariate logistic regression identified age, body mass index, CRP \ge 36 mg/L, and LDH \ge 267
- 34 U/L as significant risk factors for oxygen therapy requirement. This study suggests that elevated
- 35 CRP and LDH levels are independent risk factors for oxygen therapy in outpatients with COVID-
- 36 19. Further confirmatory studies are needed.
- 37

38 Introduction

- 39 Biomarkers can play a key role in decision making by physicians in daily practice for
- 40 patients with coronavirus disease 2019 (COVID-19) (Tabassum et al., 2021). It is important for
- 41 clinicians to identify patients requiring hospitalization. To ensure the efficient allocation of

42 medical resources, patients who require oxygen therapy should be prioritized for hospitalization43 (Yamada et al., 2021).

Vahey et al. reported that chronic hypoxemic respiratory failure with a requirement for oxygen supplementation, opioid use, metabolic syndrome, obesity, age ≥ 65 years, hypertension, arrhythmia, and male sex were significantly associated with the risk of hospitalization among patients with COVID-19 (Vahey et al., 2021). Yamada et al. created a clinical score for evaluating the need for hospitalization based on age, sex (male), BMI, medical history, and symptoms (Yamada et al., 2021). Although such information is helpful, it is sometimes difficult to precisely predict the prognosis of COVID-19 in daily practice without biomarkers.

51 Biomarkers of inflammation and coagulopathy can aid in identifying patients hospitalized 52 with COVID-19 who are at risk for clinical deterioration (Anyan et al., 2020). Poudel et al.

reported that the d-dimer level on admission is an accurate biomarker predicting mortality in
patients with COVID-19 (1.5 µg/mL is the optimal cutoff) (Poudel et al., 2021). Li et al. reported

55 that an elevated lactate dehydrogenase (LDH) level at admission is an independent risk factor for

- 56 the severity and mortality of COVID-19 (Li et al., 2020). Rahman et al. reported that C-reactive
- 57 protein (CRP), d-dimer, and ferritin levels at hospital admission represent simple assessment
- 58 factors for COVID-19 severity (Rahman et al., 2021). The neutrophil-to-lymphocyte ratio (NLR)
- is also mentioned to be a strong predictor of the prognosis for patients with severe COVID-19
- 60 using a cutoff of 4.4 (Kilercik et al., 2021). Procalcitonin may also be useful for predicting
- 61 prognosis (Hu et al., 2021). Decreased albumin and globulin levels were independent factors
- related to oxygen therapy in patients younger than 65 years who were admitted for COVID-19

63 (Ni et al., 2021). However, these studies used the data of patients who had been admitted to the

hospital. Because the biomarkers' level change during the stages of COVID-19, there appears tobe no consensus regarding the biomarkers predictive of prognosis among outpatients who require

66 admission and oxygen therapy.

67 Therefore, this study analyzed the data of outpatients to identify the biomarkers 68 predictive of the need for oxygen therapy in patients with COVID-19. Additionally, we 69 discussed the optimal cutoffs of the predictive biomarkers.

- 70
- 71
- . . 72
- 73

74 Materials & Methods

75 Study design and participants

From April 2021 to September 2021, outpatients newly diagnosed with COVID-19 who
visited Asahikawa City Hospital as new patients were enrolled in the study. All patients were

78 diagnosed by polymerase chain reaction for severe acute respiratory syndrome coronavirus 2

79 (SARS-CoV-2) genes and/or antigen quantitation testing.

80 The endpoint of this study was the requirement for oxygen therapy, which was definitely 81 administered to patients with percutaneous oxygen saturation levels of $\leq 92\%$.

82 Ethics

83 This study was approved by the ethics committee of Asahikawa City Hospital and
84 conducted in accordance with the ethical standards set forth in the Declaration of Helsinki
85 (1983). The opt-out method was used to obtain patient consent in this study.

86 Data collection

All demographic, clinical, and outcome data were retrospectively extracted from the
Asahikawa City Hospital record files. The demographic characteristics of the patients (age, sex,
body mass index [BMI]); white blood cell count (WBC); NLR; LDH, aspartate aminotransferase
(AST), alanine aminotransferase (ALT), d-dimer, and ferritin levels; comorbidities, and clinical
courses were recorded. The time from the onset of symptoms to blood sampling was also
recorded. All blood samples were taken before patients received any treatment for COVID-19.

93 Statistical analysis

94 Continuous data were analyzed using the Mann-Whitney U test and presented as the 95 mean (interquartile range). For categorical variables, Fisher's exact test or the chi-squared test 96 was used, as appropriate. The receiver operating characteristic (ROC) curve, sensitivity, 97 specificity, and area under the curve (AUC) were measured to evaluate the levels of laboratory indicators predicting the need for oxygen therapy. We considered that the best cutoff was near 98 the shoulder of the ROC curve because as the sensitivity is progressively increased, there is little 99 or no loss in specificity until extremely high levels of sensitivity are achieved. The cumulative 100 probability that patients with COVID-19 would not require oxygen therapy was described via 101 Kaplan–Meier analysis and analyzed using log-rank test. Patients who required oxygen therapy 102 103 started this treatment within 7 days after blood sampling, and thus, the analysis was performed 104 within 8 days (follow-up time) after blood sampling.

Multivariate logistic analysis was used to exploit the risk factors for oxygen therapy. P <
0.05 was considered statistically significant. Statistical analysis was performed using BellCurve
for Excel by Social Survey Research Information Co. Ltd and EZR by Saitama Medical Center,
Jichi Medical University, Saitama, Japan, which is a 120 graphical user interface for R (The R
Foundation for Statistical Computing, Vienna, 121 Austria) (Kanda et al., 2013).

110

111 Results

112 Characteristics

In total, 287 outpatients who visited Asahikawa City Hospital for the first time were
eligible for the study. We excluded five patients who were admitted to other hospitals after they
visited our hospital because the clinical course data were missing.

116 We divided the patients into two groups according to the need for oxygen therapy. S1

117 Table presents the characteristics of the 282 outpatients included in the study. Among the

118 included patients, 142 received blood tests before any treatment for COVID-19 was started. All

blood samples were collected at the outpatient setting. In total, 138 patient samples were

120 collected at the first visit to our hospital's outpatient unit. Four patient samples were collected at

121 the second or third visit. Table 1 presents the characteristics of 142 patients who underwent

- 122 blood testing. Details of their comorbidities are presented in S2 Table. Forty patients required
- 123 oxygen therapy, and the remaining patients recovered without oxygen therapy. The median
- 124 patient age was 55 (45.5–72.25) years among those requiring oxygen therapy, versus 44.5 (34.3–
- 125 52.8) years among those who did not require oxygen therapy (P < 0.001). The proportions of
- 126 males among patients who did and did not receive oxygen therapy were 57.8% and 57.5% (P >
- 127 0.999), respectively. No significant difference was found in BMI, smoking history, receipt of
- 128 SARS-CoV-2 vaccines, comorbidities, and the time from onset between the patients who did and
- 129 did not require oxygen therapy. The ROC curves of BMI and age distinguishing the need for
- 130 oxygen therapy are presented in Fig 1, and the AUCs of age and BMI were 0.699 (0.603–0.795)
- and 0.604 (0.496-0.713), respectively. The optimal cutoffs of BMI and age were 25.2 kg/m² and
- 132 52 years, respectively. The sensitivity and specificity of BMI were 0.611 and 0.619, respectively,
- 133 and those of age were 0.625 and 0.922, respectively.
- 134

135 Table 1. Characteristics of 142 outpatients who underwent blood testing

	No oxygen therapy	Oxygen therapy (n =	Р	
	(n = 102)	40)		
Demographics				
Male (%)	59 (57.8%)	23 (57.5%)	1	
Age (years), median (IQR)	44.5 (34.3–52.8)	55 (45.5–72.25)	< 0.001*	
BMI, median (IQR) (missing: 28.7%)	23.9 (21.5–27.3)	25.7 (23.1–28.6)	0.071	
Smoking, yes (%) (missing: 33.7%)	46 (47.4%)	20 (50%)	0.852	
SARS-CoV-2 vaccines, yes (%)	4 (3.9%)	3 (7.5%)	0.402	
Comorbidities (%)	40 (39.2%)	21 (52.5%)	0.211	
Time from onset (days), median (IQR)	5 (3–7)	6 (3-7.5)	0.577	
Laboratory findings				
WBC (/µL), mean (IQR)	4550 (3817.5–5460)	5315 (4157.5–9920)	0.049*	
Neutrophil-to-lymphocyte ratio, mean	2.81 (1.94-4.64)	4.74 (3.87–7.39)	<0.001*	
AST (U/L), mean (IQR)	28.5 (22.0–35.75)	39.0 (28.5–56.5)	< 0.001*	
ALT (U/L), mean (IQR)	23.0 (15.25–44.5)	25.5 (17.0-39.25)	0.462	
LDH (U/L), mean (IQR) (missing: 0.7%)	221 (188–986)	313 (264–415)	< 0.001*	


Ferritin (ng/mL), mean (IQR) (missing:	240.7 (105.5, 450.4)	165 9 (<u>214 6</u> 947 0)	0.004*
14.7%)	249.7 (105.5–450.4)	465.8 (214.6–847.0)	0.004
D-dimer (µg/mL), mean (IQR) (missing:		1.0 (0.55, 1.20)	<0.001*
14.7%)	0.3 (0.20–0.78)	1.0 (0.55–1.20)	<0.001*
CRP (mg/L), mean (IQR)	1.96 (0.66–3.21)	6.29 (3.16–9.75)	< 0.001*
			l

136 *Significant at P < 0.05

137

138

Figure 1. ROC curves of BMI and age distinguishing the need for oxygen therapy **ROC curve**



139

140 Laboratory findings


In patients requiring oxygen therapy, higher WBC (5315/µL [4157.5–9920] vs. 4550/µL 141 142 $[3817.5-5460]/\mu$ l, P = 0.049), higher NLR (4.74 [3.87-7.39] vs. 2.81 [1.94-4.64], P < 0.001), higher LDH (313 U/L [264–415] vs. 221 U/L [188–986], P < 0.001), higher CRP (62.9 mg/L 143 [31.6–97.5] vs. 19.6 mg/L [6.6–32.1], P < 0.001), higher ferritin (465.8 ng/mL [214.6–847.0] vs. 144 249.7 ng/mL [105.5–450.4], P = 0.004), and higher d-dimer (1.0 µg/mL [0.55–1.20] vs. 0.3 145 146 μ g/mL [0.20–0.78], P < 0.001) were found. ALT levels did not differ between the groups (39.0 147 U/L [28.55–56.5] vs. 28.5 U/L [22.0–35.75], P = 0.462). We selected WBC, NLR, CRP, AST, 148 and LDH as potential biomarkers predicting the need for oxygen therapy, whereas ferritin and d-149 dimer were excluded because these data were missing for 14.7% of patients. 150 The ROC curves of WBC, NLR, CRP, AST, and LDH in distinguishing the need for oxygen therapy are presented in Fig 2. Table 2 presents the AUC, P-value, cutoff, sensitivity, and 151 specificity of each variable. The AUCs of WBC, NLR, CRP, AST, and LDH for predicting the 152 153 need for oxygen therapy were 0.604, 0.730, 0.799, 0.716, and 0.774, respectively. The optimal cutoffs of WBC, NLR, CRP, AST, and LDH were 5270/µL, 3.546, 36 mg/L, 35 U/mL, and 267 154 155 U/mL, respectively. The respective sensitivity and specificity of these variables were as follows: 156 WBC, 0.683 and 0.525; NLR, 0.644 and 0.825; CRP, 0.802 and 0.725; AST, 0.723 and 0.675; 157 and LDH, 0.713 and 0.750. There was no significant difference in AUC among CRP, LDH, NLR, and AST, whereas that of WBC was significantly lower than those of the other variables (P 158

159 < 0.05). We selected CRP and LDH for further analysis because they had higher AUCs and they

- 160 are routinely used in daily practice.
- 161

162 Figure 2. ROC curves of WBC, NLR, CRP, AST, and LDH in distinguishing the need for

163 oxygen therapy



164

165 Table 2. The AUC (95% confidence interval [CI]), P-value, cutoff, sensitivity, and

166	specificity of WRC_NLR	CRP AST and LDH in	predicting the need for oxygen th	ieranv
100	specificity of which there	, CRI, ASI, and LDII III	predicting the need for oxygen ti	iciapy

	AUC	95% CI	P-value	Cutoff	Sensitivity	Specificity
WBC	0.604	0.497–0.711	0.056	5270/µL	0.683	0.525
NLR	0.730	0.635–0.825	<0.001*	3.546	0.644	0.825
CRP	0.799	0.711–0.886	<0.001*	36 mg/L	0.802	0.725
AST	0.716	0.618-0.813	<0.001*	35 U/mL	0.723	0.675
LDH	0.7743	0.689–0.856	<0.001*	267 U/mL	0.713	0.750

167

All patients in the oxygen therapy group started therapy within 7 days of blood testing.
The Kaplan–Meier distributions revealed a significant difference in the rates of oxygen therapy

between low (<35 mg/L and high ($\geq 35 \text{ mg/L}$) CRP levels (log-rank P < 0.001, Fig. 3) and

171 between low (<267 U/L) and high (\geq 267 U/L) LDH levels (log-rank P < 0.001*, Fig. 4).

172

173


174

175

176


177

- 179 Figure 3. Kaplan–Meier estimates of the cumulative probability that patients with COVID-
- 180 19 would require oxygen therapy according to plasma CRP < 36 mg/L vs. CRP \ge 36 mg/L





183 19 would require oxygen therapy according to plasma LDH < 267 U/L vs. LDH \ge 267 U/L




185Days186The results of multivariate logistic regression analysis for predicting the need for oxygen187therapy according to age, BMI, CRP \geq 36 mg/L, LDH \geq 267 U/mL, and comorbidities are188presented in Fig 5. Age, BMI, CRP, and LDH were predictive of a significantly higher need for189oxygen therapy with odds ratios (95% CIs) of 1.06 (1.02–1.10), 1.15 (1.02–1.29), 7.83 (2.45–19025.1), and 3.9 (1.14–13.3), respectively (Fig 5).

199 Fig 5. Odds ratios and 95% CIs of age, BMI, CRP, and LDH (multivariate logistic

200 regression analysis)

201



202 0.1 203 **Discussion**

This study aimed to identify useful laboratory findings predicting the need for oxygen therapy among outpatients with COVID-19. In multivariate analysis, $CRP \ge 36$ mg/L, and LDH ≥ 267 U/L are independent risk factors for oxygen therapy. CRP and LDH are widely used and inexpensive to measure. Our findings will help physicians during the management of COVID-19 by indicating the need for frequent follow-up or therapies to avoid poor prognoses.

Excessive inflammation is considered the main cause of critical illness and death in 209 210 patients with COVID-19 (Luan et al., 2021). CRP levels are obviously increased in the presence of acute inflammation, and they might normalize after inflammation subsides (Luan et al., 2021). 211 CRP levels in the early stage of COVID-19 have been reported to be positively correlated with 212 the presence of lung lesions (Wang et al., 2020). During the process of COVID-19 pneumonia, a 213 214 cytokine response storm can be triggered, which is associated with high mortality in COVID-19 (Azar et al., 2020). Because the CRP level varies by stage of inflammation, the CRP cutoff 215 predicting severity should change according to the stage. $CRP \ge 110 \text{ mg/L}$ is associated with 216 217 moderate-to-severe acute respiratory distress syndrome in patients with COVID-19 (Poggiali et 218 al., 2020). Patients with CRP > 64.75 mg/L on admission were more likely to have severe 219 complications of COVID-19 (Sadeghi-Haddad-Zavareh et al., 2021). Stringer et al. reported that a CRP cutoff of \geq 40 mg/L on admission was a good indicator of mortality in patients with 220 221 COVID-19 (Stringer et al., 2021). These previous studies focused on CRP levels at admission to 222 predict disease severity. Our study therefore provides useful information by suggesting a CRP cutoff of \geq 36 mg/L for identifying outpatients who will require oxygen therapy. 223

LDH is an inflammatory marker that may serve as a common indicator of acute or severe
tissue damage (Sepulveda et al., 2019). Cytokine-mediated lung tissue damage, which is a
primary feature of COVID-19, may be responsible for the elevated release of LDH (MartinezOutschoorn et al., 2011). LDH ≥ 450 U/L on hospitalization was associated with moderate-to-

severe acute respiratory distress syndrome in patients with COVID-19 (Poggiali et al., 2020). Li et al. reported that LDH levels of \geq 359.5 and \geq 277 U/L at admission was associated with death and severe COVID-19, respectively (Li et al., 2020). Although this report used the serum LDH level at admission, the result was similar to those of our study, which suggested that LDH \geq 267 U/L in outpatients with COVID-19 was predictive of the need for oxygen therapy. Additionally, in multivariate analysis, serum LDH \geq 267 U/mL remained an independent risk factor for oxygen therapy in our study, in line with the results of Li et al.

- 235 Our findings suggest that both CRP \geq 36 mg/L and LDH \geq 267 U/L are useful for 236 identifying patients who will require oxygen support in the near future, and there was no 237 statistical difference in the AUC between these variables. We used patients' samples obtained at 238 their visits, and the samples were obtained a median of 5 days after symptom onset in the 239 nonoxygen therapy group and a median of 6 days in the oxygen therapy group. Meanwhile, 240 patients who needed oxygen support started within 7 days of blood sampling. Because LDH and 241 CRP levels exhibit dynamic changes during the progression of COVID-19, the interval from 242 symptom onset to blood testing should be considered when physicians devise patients' treatment
- strategies.

244 In this study, BMI, age, and comorbidities were also analyzed in a multivariate regression model because they are well-known prognostic factors for COVID-19. The US Food and Drug 245 246 Administration published criteria for the use of monoclonal antibodies to treat or prevent SARS-247 CoV-2 in consideration of risk factors including older age (≥ 65 years), obesity (BMI > 25 kg/m²) in adults), pregnancy, and comorbidities such as chronic kidney disease, diabetes, and chronic 248 lung disease (US Food and Drug Administration., 2021). BMI > 25 kg/m² was similar to our 249 250 cutoff of 25.2 kg/m², but the number the cases was limited in our analysis. However, our analysis assessed all comorbidities collectively because we did not have sufficient numbers of 251 participants to analyze comorbidities separately. The criteria of the Japanese Ministry of Health, 252 Labor and Welfare indicated that patients younger than 50 years are eligible for monoclonal 253 254 antibody therapy as high-risk patients (Japanese Ministry of Health, Labor and Welfare., 2021). 255 Our age cutoff of 52 years was similar to these criteria.

Regarding study limitations, the number of cases was limited, and this study was 256 performed retrospectively at a single hospital. Only some patients underwent blood testing at 257 258 their visit based on the judgment of the physicians. Only 4.93% of patients received SARS-CoV-2 vaccines in this study, and the cutoffs might differ according to the receipt of vaccination. 259 Ferritin and d-dimer levels also significantly differed between patients who did and did not 260 receive oxygen therapy; however, the physicians did not measure these parameters in 14.7% of 261 patients. Because all patients were ethnically Japanese, the results should be verified in other 262 263 populations. Further studies are needed to confirm our findings.

- 264
- 265
- 266
- 267

268 **Conclusions**

- This study suggests that $CRP \ge 36 \text{ mg/L}$, and $LDH \ge 267 \text{ U/L}$ are independent risk factors for oxygen therapy. Further studies concerning biomarkers will help physicians during the management of COVID-19.
- 272

277

273 Supporting information

- 274 S1 Table. Characteristics of 282 outpatients who visited our hospital during the study
- 275 period
- 276 S2 Table. Comorbidities of 142 patients who underwent blood testing

278 Acknowledgements

- The authors thank all the participating physicians and other medical staffs for their care of patients with COVID-19.
- 281 COVID-19 medical team: Ai Nakamura, Akihito Tampo, Akiko Irie, Akito Uehara, Hidemitsu
- 282 Sakagami, Kae Takahashi, Kazuki Yamada, Masahide Nakajima, Seisuke Saito, Shin Kukita,
- 283 Shohei Kuroda, Roku Sato, Yuji Naito, Yuuki Nagasima
- 284

285 **References**

- 286 Tabassum T, Rahman A, Araf Y, Ullah MA, Hosen MJ. Prospective selected biomarkers in
- 287 COVID-19 diagnosis and treatment. Biomark Med. 2021;15: 1435-1449. doi:
- 288 http://doi.org/10.2217/bmm-2021-0038 PMID: 34538093
- 289 Yamada G, Hayakawa K, Matsunaga N, Terada M, Suzuki S, Asai Y, Otsu H, Toyada A,

290 Kitajima K, Tsuzuki S. Predicting respiratory failure for COVID-19 patients in Japan: a simple

clinical score for evaluating the need for hospitalisation. Epidemiol Infect. 2021;149: e175(19).

- 292 doi: https://doi.org/10.1017/S0950268821001837
- 293 Vahey GM, McDonald E, Marshall K, Martin SW, Chun H, Herlihy R, Tate JE, Kawasaki B,
- 294 Midgley CM, Alden N, Killerby ME, Staples JE, Colorado Investigation Team. Risk factors for
- hospitalization among persons with COVID-19-Colorado. PLoS One. 2021;16: e0256917. doi:
- 296 https://doi.org/10.1371/journal.pone.0256917 PMID: 34473791
- 297 Ayanian S, Reyes J, Lynn L, Teufel K. The association between biomarkers and clinical
- outcomes in novel coronavirus pneumonia in a US cohort. Biomark Med. 2020;14: 1091-1097.
- 299 doi: https://doi10.2217/bmm-2020-0309. PMID: 32677844
- 300 Poudel A, Poudel Y, Adhikari A, Aryal BB, Dangol D, Bajracharya T, Maharjan A, Gautam R.
- 301 D-dimer as a biomarker for assessment of COVID-19 prognosis: D-dimer levels on admission
- 302 and its role in predicting disease outcome in hospitalized patients with COVID-19. PLoS One.
- 303 2021;16: e0256744. doi: https://doi.org/10.1371/journal.pone.0256744. PMID: 34437642
- 304 Li C, Ye J, Chen Q, Hu W, Wang L, Fan Y, Lu Z, Chen J, Chen Z, Chen S, Tong J, Xiao W,
- 305 Mei J, Lu H. Elevated lactate dehydrogenase (LDH) level as an independent risk factor for the
- 306 severity and mortality of COVID-19. Aging. 2020;12: 15670-15681. doi:
- 307 https://doi.org/10.18632/aging.103770. PMID: 32805722

- 308 Rahman MA, Shanjana Y, Tushar MI, Mahmud T, Rahman GMS, Milan ZH, Sultana T,
- 309 Chowdhury AMLH, Bhuiyan MA, Islam MR, Reza HM. Hematological abnormalities and
- 310 comorbidities are associated with COVID-19 severity among hospitalized patients: Experience
- 311 from Bangladesh. PLoS One. 2021;16: e0255379. doi:
- 312 https://doi.org/10.1371/journal.pone.0255379. PMID: 34314447
- 313 Kilercik M, Demirelce Ö, Serdar MA, Mikailova P, Serteser M. A new haematocytometric
- 314 index: Predicting severity and mortality risk value in COVID-19 patients. PLoS One. 2021;16:
- 315 e0254073. doi: https://doi.org/10.1371/journal.pone.0254073. PMID: 34351940
- 316 Hu R, Han C, Pei S, Yin M, Chen X. Procalcitonin levels in COVID-19 patients. Int J
- 317 Antimicrob Agents. 2020;56: 106051. doi: https://doi.org/10.1016/j.ijantimicag.2020.106051.
- 318 PMID: 32534186
- 319 Ni YN, Wang T, Liang BM, Liang ZA. The independent factors associated with oxygen therapy
- 320 in COVID-19 patients under 65 years old. PLoS One. 2021;16: e0245690. doi:
- 321 https://doi.org/10.1371/journal.pone.0245690. PMID: 33481912
- 322 Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics.
- 323 Bone Marrow Transplant. 2013;48: 452-458. doi: https://doi.org/10.1038/bmt.2012.244. PMID:

- Luan YY, Yin CH, Yao YM. Update advances on C-reactive protein in COVID-19 and other viral infections. Front Immunol. 2021;12: 720363. doi:
- 327 https://doi.org/10.3389/fimmu.2021.720363. PMID: 34447386
- 328 Wang L. C-reactive protein levels in the early stage of COVID-19. Med Mal Infect. 2020;50:
- 329 332-334. https://doi.org/10.1016/j.medmal.2020.03.007. PMID: 32243911
- Azar MM, Shin JJ, Kang I, Landry M. Diagnosis of SARS-CoV-2 infection in the setting of the
- 331 cytokine release syndrome. Expert Rev Mol Diagn. 2020;20: 1087-1097. doi:
- 332 https://doi.org/10.1080/14737159.2020.1830760. PMID: 32990479
- 333 Poggiali E, Zaino D, Immovilli P, Rovero L, Losi G, Dacrema A, Nuccetelli M, Vadacca GB,
- 334 Guidetti D, Vercelli A, Magnacavallo A, Bernardini S, Terrracciano C. Lactate dehydrogenase
- and C-reactive protein as predictors of respiratory failure in CoVID-19 patients. Clin Chim Acta.
- **336** 2020;509: 135-138. doi:
- 337 https://doi.org/10.1016/j.cca.2020.06.012. PMID: 32531257
- 338 Sadeghi-Haddad-Zavareh M, Bayani M, Shokri M, Ebrahimpour S, Babazadeh A, Mehraeen R,
- 339 Moudi E, Rostami A, Barary M, Hosseini A, Bijani A, Javanian M. C-reactive protein as a
- 340 prognostic indicator in COVID-19 patients. Interdiscip Perspect Infect Dis. 2021: 5557582. doi:
- 341 https://doi.org/10.1155/2021/5557582. PMID: 33968148
- 342 Stringer D, Braude P, Myint PK, Evans L, Collins JT, Verduri A, Quinn TJ, Vilches-Moraga A,
- 343 Stechman MJ, Pearce L, Moug S, McCarthy K, Hewitt J, Carter B, COPE Study Collaborators.
- The role of C-reactive protein as a prognostic marker in COVID-19. Int J Epidemiol. 2021;50:
- 345 420-429. doi: https://doi.org/10.1093/ije/dyab012. PMID: 33683344

- 346 Sepulveda JL. Challenges in routine clinical chemistry analysis: proteins and enzymes. In:
- Accurate results in the clinical laboratory 2019. Pp. 141-163. doi: https://doi.org/10.1016/B9780-12-813776-5.00010-8
- 240 Martiner Ostalia and LIE Drive M Estal A Trivier
- 349 Martinez-Outschoorn UE, Prisco M, Ertel A, Tsirigos A, Lin Z, Pavlides S, Wang C,
- 350 Flomenberg N, Knudsen ES, Howell A, Pestell RG, Sotgia F, Lisanti MP. Ketones and lactate
- 351 increase cancer cell "stemness," driving recurrence, metastasis and poor clinical outcome in
- 352 breast cancer: achieving personalized medicine via Metabolo-Genomics. Cell Cycle. 2011;10:
- 353 1271-1286. doi: https://doi.org/10.4161/cc.10.8.15330. PMID: 21512313
- 354 US Food and Drug Administration. Fact Sheet for Health Care Providers: Emergency Use
- 355 Authorization (EUA) of REGEN-COV (Casirivimab with Imdevimab). [Cited 2021 November
- 356 16]. Available from: https://www.fda.gov/media/145611/download
- 357 Japanese Ministry of Health, Labour and Welfare. Shingata Korona Uirus Kansensho no tebiki
- dai 6 han. [Cited 2021 November 16] Available from:
- 359 https://www.mhlw.go.jp/content/000851082.pdf (Japanese)